

### **AMENDMENTS TO THE CLAIMS**

1. (Currently amended) A method of screening for a compound or a salt thereof, that changes the binding property of a G protein-coupled receptor protein comprising ~~the same or substantially the same amino acid sequence as~~ the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6 ~~any one of SEQ ID NO: 3 through SEQ ID NO: 7, its amide, or a salt thereof, or signal transduction, which the method comprising: is characterized by using~~ (1) contacting said receptor protein, ~~its partial peptide, or a salt thereof, and~~ (2) with said ligand peptide, its amide, or a salt thereof, and determining a level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, and in the absence of said compound or salt thereof, wherein a difference in binding levels by said ligand peptide, its amide or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, compared to in the absence of said compound or salt thereof, indicates that the compound changes the binding property of said receptor protein to said ligand peptide.
2. (Currently amended) A method of screening for an agonist or antagonist ~~to~~ of a G protein-coupled receptor protein comprising ~~the same or substantially the same amino acid sequence as~~ the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, ~~which is characterized by using~~ (1) the method comprising contacting said receptor protein, ~~or its partial peptide, or a salt thereof, and~~ (2) a ~~with~~ compound or a salt thereof ~~that changes the binding property of a ligand peptide comprising the amino acid sequence represented by~~ SEQ ID NO:6 ~~any one of SEQ ID NO: 3 through SEQ ID NO: 7, its amide, or a salt thereof, to said receptor protein~~

~~or a salt thereof, or signal transduction and determining a change in a binding property of said G protein-coupled receptor protein-level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof, in the presence of a test compound or salt thereof, and in the absence of said compound or salt thereof; wherein a decrease in binding levels by said ligand peptide, its amide or salt thereof, in the presence of said test compound or salt thereof, compared to in the absence of said test compound, indicates said test compound is an antagonist.~~

3. (Currently amended) A kit for screening a compound or a salt thereof, that changes the binding property of a G protein-coupled receptor protein comprising ~~the same or substantially the same amino acid sequence as~~ the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, ~~any one of SEQ ID NO: 3 through SEQ ID NO: 7, its amide, or a salt thereof, or signal transduction, which is characterized by (1)~~ wherein said kit comprises said receptor protein, its partial peptide, or a salt thereof, and (2) said ligand peptide, its amide, or a salt thereof.
4. (Currently amended) A kit for screening for an agonist or antagonist to a G protein-coupled receptor protein comprising ~~the same or substantially the same amino acid sequence as~~ the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, wherein said kit comprises ~~which is characterized by (1) said receptor protein, or its partial peptide, or a salt thereof, and (2) a compound or a salt thereof that changes the binding property of a~~ ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, ~~any one of SEQ ID NO: 3 through SEQ ID NO: 7, its amide, or a salt thereof, to said receptor protein or a salt thereof, or signal transduction.~~

5. (Withdrawn) A pharmaceutical comprising a compound or a salt thereof that changes the binding property of a ligand peptide comprising the amino acid sequence represented by any one of SEQ ID NO: 3 through SEQ ID NO: 7, its amide, or a salt thereof, to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, or signal transduction.
6. (Withdrawn) The pharmaceutical according to claim 5, which is an agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer.
7. (Withdrawn) A method of screening an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which is characterized by assaying an intracellular cAMP production inhibition activity in the case where a test compound is brought in contact with a cell containing said receptor protein.

8. (Withdrawn) An agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which comprises a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.
9. (Withdrawn) An agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial

infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which comprises a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof.

10. (Withdrawn) A diagnostic agent for asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which comprises a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof.
11. (Withdrawn) An agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism,

cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which comprises an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof.

12. (Withdrawn) A diagnostic agent for asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome,

immunodeficiency, infections or cancer, which comprises an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof.

13. (Withdrawn) An agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which comprises the entire or part of a base sequence complementary to a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof.
14. (Withdrawn) A method for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's

disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which is characterized by administering to a mammal an effective dose of (i) a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof, (ii) a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof, or (iii) an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.

15. (Withdrawn) A method for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary



sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer, which is characterized by administering to a mammal an effective dose of (i) an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof, (ii) a polynucleotide comprising the entire or part of a base sequence complementary to a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof, or (iii) an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof.

16. (Withdrawn) Use of (i) a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof, (ii) a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof, or (iii) an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to manufacture an agent for preventing/treating asthma, allergic disease, inflammation, inflammatory

eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer.

17. (Withdrawn) Use of (i) an antibody to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof, (ii) a polynucleotide comprising the entire or part of a base sequence complementary to a polynucleotide comprising a polynucleotide encoding a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a partial peptide thereof, or (iii) an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to manufacture an agent for preventing/treating asthma, allergic disease, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head injury, spinal cord injury, cerebral edema, multiple

sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy, meningitis, diabetes mellitus, chronic articular rheumatism, arthritis deformans, rheumatoid spondylitis, gouty arthritis, synovitis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, viral infections, angina pectoris, myocardial infarction, congestive heart failure, hepatitis, posttransplantational hyperimmunization, dialysis hypotension, disseminated intravascular coagulation syndrome, immunodeficiency, infections or cancer.

18. (New) A method of screening for a compound or a salt thereof, that changes the binding property of a G protein-coupled receptor protein comprising the amino acid sequence having at least 85% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof, the method comprising: contacting said receptor protein, or a salt thereof, with said ligand peptide, its amide, or a salt thereof, and determining a level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, and in the absence of said compound or salt thereof, wherein a difference in binding levels by said ligand peptide, its amide or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, compared to in the absence of said compound or salt thereof, indicates that the compound changes the binding property of said receptor protein to said ligand peptide.
19. (New) A method of screening for an agonist or antagonist of a G protein-coupled receptor protein comprising the amino acid sequence having at

least 85% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, the method comprising contacting said receptor protein, or a salt thereof, with a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof, and determining a level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof; in the presence of a test compound or salt thereof, and in the absence of said compound or salt thereof, wherein a decrease in binding levels by said ligand peptide, its amide or salt thereof, in the presence of said test compound or salt thereof, compared to in the absence of said test compound or salt thereof, indicates said test compound is an antagonist.

20. (New) A kit for screening a compound or a salt thereof, that changes the binding property of a G protein-coupled receptor protein comprising the amino acid sequence having at least 85% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof, wherein said kit comprises- said receptor protein, or a salt thereof, and (2) said ligand peptide, its amide, or a salt thereof.
21. (New) A kit for screening for an agonist or antagonist to a G protein-coupled receptor protein comprising the amino acid sequence having at least 85% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, wherein said kit comprises (1) said receptor protein, or a salt thereof, and (2) a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof.
22. (New) A method of screening for a compound or a salt thereof, that changes the binding property of a G protein-coupled receptor protein

comprising the amino acid sequence having at least 95% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, to a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof, the method comprising: contacting said receptor protein, or a salt thereof, with said ligand peptide, its amide, or a salt thereof, and determining a level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, and in the absence of said compound or salt thereof, wherein a difference in binding levels by said ligand peptide, its amide or salt thereof, to said receptor protein or salt thereof, in the presence of said compound or salt thereof, compared to in the absence of said compound or salt thereof, indicates that the compound changes the binding property of said receptor protein to said ligand peptide.

23. (New) A method of screening for an agonist or antagonist of a G protein-coupled receptor protein comprising the amino acid sequence having at least 95% homology to the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, the method comprising contacting said receptor protein, or a salt thereof, with a ligand peptide comprising the amino acid sequence represented by SEQ ID NO:6, its amide, or a salt thereof, and determining a level of binding by said ligand peptide, its amide, or salt thereof, to said receptor protein or salt thereof; in the presence of a test compound or salt thereof, and in the absence of said compound or salt thereof, wherein a decrease in binding levels by said ligand peptide, its amide or salt thereof, in the presence of said test compound or salt thereof, compared to in the absence of said test compound or salt thereof, indicates said test compound is an antagonist.